Pharmaceutical compositions comprising gels and methods for fabricating thereof
Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described.
1. An ophthalmological pharmaceutical composition consisting of a quantity of timolol, a quantity of latanaprost and a quantity of poly(oxyethylene-co-oxypropylene) block copolymer in concentration between about 1.0 mg/mL and about 150.0 mg/mL, wherein the composition is a gel at a temperature that is at least about human body temperature and is a fluid at a temperature that is lower than about the body temperature.
2. The ophthalmological pharmaceutical composition of claim 1 , wherein the concentration of timolol and latanaprost in the composition is between about 0.1 mg/mL and about 100.0 mg/mL.
3. The ophthalmological pharmaceutical composition of claim 2 , wherein the concentration of timolol and latanaprost in the composition is between about 1.0 mg/mL and 50.0 mg/mL.
4. The ophthalmological pharmaceutical composition of claim 3 , wherein the concentration of timolol and latanaprost in the composition is about 25.0 mg/mL.
5. An ophthalmological pharmaceutical composition consisting of a quantity of timolol, a quantity of latanaprost and a quantity of poly(oxyethylene-co-oxypropylene) block copolymer in concentration between about 1.0 mg/mL and about 150.0 mg/mL, and a quantity of a second polymer selected from the group consisting of poly(N-isopropylacrylamide), poly(N-isopropylacrylamide-co-acrylic acid), poly(vinyl pyrrolidone), poly(4-vinylpyridine-co-ethylacrylate) block copolymer, poly(N-isopropylacrylamide-co-butyl methacrylate-co-ethylene glycol) block copolymer and combinations thereof, wherein the composition is a gel at a temperature that is at least about human body temperature and is a fluid at a temperature that is lower than about the body temperature.
6. The ophthalmological pharmaceutical composition of claim 5 , wherein the concentration of timolol and latanaprost in the composition is between about 0.1 mg/mL and about 100.0 mg/mL.
7. The ophthalmological pharmaceutical composition of claim 6 , wherein the concentration of timolol and latanaprost in the composition is between about 1.0 mg/mL and 50.0 mg/mL.
8. The ophthalmological pharmaceutical composition of claim 7 , wherein the concentration of timolol and latanaprost in the composition is about 25.0 mg/mL.